Lead asset

JFIN-0007-G2 · MS pipeline

An anti-CD74 VHH nanobody targeting the MIF binding site, designed entirely in silico. Honest status: extensive validation done; wet-lab production starts when our CSIC collaboration confirms.

JFIN-0007-G2

G2 — anti-CD74 VHH

Nanobody designed to block the MIF binding site on the CD74 trimerization domain. Validated by AlphaFold 3 (iPTM 0.297 ± 0.029, 4 seeds), molecular dynamics (10 ns stable complex), and developability suite (Aggrescan3D, NetMHCIIpan, CamSol).

Modality

VHH · 15 kDa

Target

CD74 / MIF

Indication

Multiple Sclerosis (RRMS)

Stage

In silico validation

Progress

Updated weekly

Target identified via scGPT single-cell analysis

VHH library generated (294 candidates after composition filters)

AlphaFold 3 multi-seed validation completed

Developability + MD stability confirmed

Wet-lab production via CSIC collaboration

Binding assay (SPR/BLI) — go/no-go decision

Transparency: This molecule has not yet been produced or tested in vitro. All current data is computational. We're publishing the wet-lab results as they come in.
Talk to us about partnering